The Week in Blood Pressure & Wearables — August 22–28, 2026
Every week we sort through the real signal in blood pressure and wearable health tech news, separate it from the diet listicles and market-research noise, and pull out what actually matters for clinicians, RPM programs, and the patients they manage. This week's biggest story is a wearable company's quiet admission that a cleared blood pressure cuff still beats an algorithm on your wrist, delivered through a brand-new Medicare payment model that every RPM company in hypertension care needs to understand.
Devices & Wearables
WHOOP launched Connected Care on August 12, 2026, a program that pairs its wearable membership with an FDA-cleared blood pressure cuff for eligible Original Medicare beneficiaries who have at least one qualifying cardio-kidney-metabolic condition. The program, which runs through WHOOP Physician Services, PC, operates within the CMS ACCESS Model, launched live in 14 states, and is free to eligible patients. We go deep on why this launch matters below, because it says something important about where cuffless blood pressure measurement actually stands in 2026.
Huawei will unveil the Watch D3 at a Munich event on September 2, 2026, according to [Huawei's announcement](https://www.morningstar.com/news/pr-newswire/20260827cn32083/huawei-to-unveil-flagship-wearables-at-munich-chase-the-wild-campaign-event-on-sept-2). The watch is described as a blood-pressure-monitoring device and continues Huawei's Watch D line, which has never received FDA clearance and is sold mainly outside the United States. It is worth tracking because it is one of the more clinically-oriented wrist form factors on the market, using a small inflatable cuff mechanism rather than pure optical estimation, but the US regulatory silence on it remains notable.
Abbott received FDA authorization on August 25, 2026 for the Libre Duo 10 Day, described as the world's first dual glucose-ketone sensing biowearable for people with diabetes, according to [Abbott's announcement](https://abbott.mediaroom.com/2026-08-25-Abbott-receives-FDA-authorization-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes). The sensor continuously tracks both glucose and rising ketone levels, giving patients on insulin an early warning for diabetic ketoacidosis risk that previously required separate fingerstick or lab testing. It is a real clearance for a real clinical claim, and a useful contrast to some of the wellness-labeled wearable features below.
Google introduced Health Guardian alongside the Pixel Watch 5 on August 12, 2026, adding monthly trend summaries for blood pressure, insulin resistance, and sleep breathing quality, per [Google's blog post](https://blog.google/products-and-platforms/products/google-health/pixel-watch-health-guardian/). Every one of these features is explicitly labeled general wellness and informational only. Google states plainly that Health Guardian is not a pre-screener for diabetes, hypertension, or sleep apnea, does not provide real-time clinical readings, and should not be used to adjust medications or treatment plans. That label matters more than the feature itself, and we come back to it in the deep dive.
Policy & Regulation
CMS's ACCESS Model is the regulatory backbone behind this week's biggest device story. Advancing Chronic Care with Effective Scalable Solutions, or ACCESS, is a ten-year voluntary CMS Innovation Center model that pays Medicare-enrolled providers for technology-supported chronic care, with a meaningful share of that payment contingent on hitting clinical outcome targets rather than simply delivering the technology. CMS describes the model's intent in its own [newsroom post on outcome-aligned payments](https://www.cms.gov/newsroom/blog/improving-access-technology-supported-care-outcome-aligned-payments). It launched July 5, 2026, and WHOOP's Connected Care program is the first consumer wearable brand to publicly build a Medicare offering directly on top of it.
The FDA named Dexcom the first participant in its TEMPO pilot on July 22, 2026, per the [FDA's press announcement](https://www.fda.gov/news-events/press-announcements/fda-announces-first-participant-selected-tempo-digital-health-devices-pilot). TEMPO lets selected digital health devices operate without full premarket authorization while the FDA collects real-world performance data, working in tandem with the CMS ACCESS Model's clinical use areas. It is an early but concrete signal that the FDA is willing to loosen its normal clearance timeline for chronic-care devices that agree to submit to structured post-market surveillance, which is a meaningfully different posture than the enforcement approach it took with WHOOP a year earlier.
Chronic care management billing is drawing fresh compliance attention. A [Compliance Clinic spotlight from McDermott Will & Schulte](https://www.mcdermottlaw.com/insights/the-compliance-clinic-chronic-care-management-spotlight/) flags CCM as an area of rising audit risk and enforcement activity, and urges CCM investors and providers to get ahead of OIG and payor scrutiny on billing accuracy before it becomes a liability. For any RPM or CCM operator building recurring Medicare revenue on these codes, this is a reminder that the compliance bar is rising in step with the reimbursement opportunity.
Hospital CIOs remain skeptical of HHS Secretary Robert F. Kennedy Jr.'s stated goal of putting a wearable on every American. A year after he set the target, HHS has not published metrics tracking progress toward it, and health system technology leaders quoted in [Becker's Hospital Review](https://www.beckershospitalreview.com/healthcare-information-technology/innovation/adoption-alone-does-not-improve-health-cios-still-cold-on-rfk-jr-s-wearables-goal/) argue that wearable data governance and clinical validation still lag the pace of device adoption. It is a useful counterweight to this week's device news: distribution is not the hard problem in wearable health tech anymore, trustworthy clinical interpretation is.
Clinical & Research
Hypertensive disorders of pregnancy have risen 73 percent in the United States since 2016, according to new CDC data covered by [KERA News](https://www.keranews.org/health-wellness/2026-08-24/cdc-study-finds-substantial-increase-in-cases-of-high-blood-pressure-in-pregnant-women) and [Axios](https://www.axios.com/2026/07/29/high-blood-pressure-pregnancy-preeclampsia-cdc-rate). The condition now affects roughly one in ten US births and the increase has occurred in every state, not just a handful of high-risk regions. This is exactly the kind of population trend that makes home blood pressure monitoring during pregnancy, not just at prenatal visits, a genuine clinical priority rather than a nice-to-have.
A meta-analysis of nine clinical trials found that poor adherence to blood pressure medication is erasing much of its cardiovascular benefit, according to a [European Society of Cardiology press release](https://www.escardio.org/news/press/press-releases/patients-are-missing-out-on-the-cardiovascular-benefits-of-blood-pressure-lowering-medicines/). Patients who took their prescribed antihypertensives as directed saw meaningfully greater reductions in cardiovascular events than those who did not, underscoring that the biggest gap in hypertension care is often not the prescription, it is what happens after the patient leaves the office. This is precisely the gap remote monitoring and structured chronic care management programs exist to close.
Researchers reported an AI model that estimates blood pressure and screens for diabetes from a single facial video, with a mean absolute percentage error of 8.6 percent for systolic blood pressure, per the [European Society of Cardiology](https://www.escardio.org/news/press/press-releases/ai-based-diagnosis-of-hypertension-and-diabetes-from-a-single-facial-video/). It is an early-stage research result, not a cleared or validated clinical tool, but it adds to a growing pile of contactless blood pressure estimation approaches competing for legitimacy against the oscillometric cuff that remains the clinical gold standard.
A new study links wearable-detected hormone patterns to a common, often-missed cause of high blood pressure, according to [News-Medical](https://www.news-medical.net/news/20260826/Wearable-device-detects-hidden-hormone-patterns-behind-high-blood-pressure.aspx). The research points to hormone-driven, secondary hypertension, the kind current guidelines already recommend screening for in resistant cases, and suggests wearable data could eventually help flag patients who need that workup sooner. It is a good example of wearables playing a genuinely useful triage role without needing to replace clinical-grade measurement.
Also Worth a Glance
Oura is reportedly targeting a September 2026 IPO at a valuation north of $16 billion, per [TechCrunch](https://techcrunch.com/2026/08/24/oura-is-reportedly-eyeing-a-september-ipo-that-could-value-it-at-more-than-16b/), even as it faces a class-action lawsuit over its sleep-tracking accuracy claims, covered by [ZDNET](https://www.zdnet.com/article/lawsuit-oura-sleep-tracking-accuracy/). The two stories sitting side by side, a record valuation and a lawsuit over measurement accuracy, is its own small case study in the gap between wearable hype and wearable validation.
The Deep Dive: WHOOP's Medicare Launch Just Answered the Cuffless Blood Pressure Question
Here is the part of this week's news that should get real attention from anyone building or evaluating a hypertension RPM program: WHOOP just told us, in the clearest possible way, that its own wrist-based blood pressure feature is not good enough to put in front of Medicare patients whose care depends on the number.
Rewind a year. WHOOP received an FDA warning letter over its Blood Pressure Insights feature, a wrist-based tool that inferred blood pressure trends from optical and motion sensors without being a cleared measurement device. The dispute dragged through the spring, and the FDA closed the warning letter in June 2026 after WHOOP adjusted how the feature was described and positioned, according to [STAT News](https://www.statnews.com/2026/06/23/fda-drops-enforcement-against-wearable-maker-whoop/) and the [FDA's own warning letter record](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/whoop-inc-709755-06172026). WHOOP kept the wrist-based trends. It just stopped implying they were a substitute for a real blood pressure reading.
Two months later, WHOOP launched Connected Care. And when the company needed to put a real, reimbursable blood pressure reading in front of Medicare beneficiaries with cardio-kidney-metabolic conditions, it did not lean more heavily on the wrist algorithm. It shipped an FDA-cleared blood pressure cuff to those patients.
That sequence is the story. A company with enormous engineering resources, a direct financial incentive to make wrist-based blood pressure work, and a full year of regulatory back-and-forth with the FDA still concluded that the path to a Medicare-grade clinical claim runs through a cleared cuff, not a wrist estimate. Google reached the same conclusion with Health Guardian the same week, explicitly labeling its own blood pressure trend feature as a general wellness feature and stating that it is not a hypertension pre-screener. Two of the best-resourced consumer health tech companies in the world landed in the same place within weeks of each other.
We have opinions on this because we lived it. Cardiowell went through FDA 510(k) clearance for our BT107 blood pressure device, as a hypertension-focused RPM company built specifically to serve Medicare patients and the clinics that manage them. That process is not fast, not cheap, and not optional if the number you are producing is going to drive a medication change. It exists because a blood pressure reading that steers clinical decisions has to meet a measurement standard that a consumer wellness algorithm, however sophisticated, has not yet met and, on the evidence of this week, still has not met even at WHOOP and Google's level of resourcing.
The debate over cuffless, wearable blood pressure accuracy has been simmering for years. This week gave it the clearest real-world answer so far, and it came from the industry's own actions rather than from a regulator's ruling. When the money and the medical liability are real, the cuff wins.
What makes this week different is the payment model wrapped around it. CMS's ACCESS Model is a genuine attempt to pay for chronic care outcomes rather than just for chronic care technology, and that is in the right direction. But WHOOP's entry into ACCESS through Connected Care also previews a competitive dynamic every smaller, purpose-built RPM company should watch closely. WHOOP is not winning Medicare access on the strength of a superior measurement device. It is winning it on the strength of an enormous existing subscriber base, brand recognition, and the ability to bundle a cleared cuff into an experience patients already know. That is a real advantage, and it is one that purpose-built hypertension RPM companies will need to compete against with something WHOOP does not have: a program built from day one around the clinical workflow, not around retrofitting a wellness brand into one.
The ACCESS Model's outcome-based structure should reward exactly that kind of program if CMS holds the line on what counts as a real outcome, not just a delivered device. That is the detail worth watching over the next year, more than any single product launch.
The Thread This Week
Pull these stories together, and one thread runs through nearly all of them: the industry is finally being forced to separate wellness signal from clinical-grade measurement, and Medicare's new payment structure is the mechanism forcing that separation into the open. WHOOP shipped a cleared cuff rather than trusting its own wrist-based algorithm. Google labeled its blood pressure trends as wellness-only rather than diagnostic. The CDC's pregnancy hypertension data and the adherence research both point to the same underlying gap, which is that a number only helps if someone acts on it correctly and consistently. None of that gets solved by a smarter sensor. It gets solved by devices that are actually cleared for the claim they make, paired with the clinical workflow and reimbursement structure to act on the reading. That is the whole premise this column keeps coming back to, and this week the biggest names in the industry backed it up with their own product decisions.